Table 1.
Associations of clinical indicators and DDX60 expression levels with total survival in training data.
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| HR (95% CI) | p values | HR (95% CI) | p values | ||
| Radiotherapy | |||||
| Yes | 195 (55.71%) | 0.729 (0.372–1.426) | 0.356 | 0.663 (0.280–1.571) | 0.351 |
| No | 155 (44.29%) | 1.000 | 1.000 | ||
| Age | |||||
| ≥60 | 166 (47.43%) | 2.424 (1.227–4.789) | 0.011 | 2.404 (1.076–5.372) | 0.033 |
| <60 | 179 (51.14%) | 1.000 | 1.000 | ||
| NA | 5 (1.43%) | ||||
| History of other malignancies | |||||
| Yes | 14 (4.00%) | 2.768 (0.655–11.700) | 0.166 | 1.334 (0.255–6.966) | 0.732 |
| No | 336 (96.00%) | 1.000 | 1.000 | ||
| Histologic type | |||||
| IDC | 232 (66.29%) | 0.830 (0.379–1.817) | 0.641 | 1.514 (0.569–4.033) | 0.406 |
| MBC | 28 (8.00%) | 0.703 (0.185–2.671) | 0.604 | 1.971 (0.469–8.291) | 0.355 |
| ILC | 83 (23.71%) | 1.000 | 1.000 | ||
| NA | 7 (2.00%) | ||||
| First surgical procedure | |||||
| Lumpectomy | 83 (23.71%) | 0.387 (0.071–2.113) | 0.273 | 0.430 (0.069–2.666) | 0.364 |
| Modified radical mastectomy | 120 (34.29%) | 2.442 (0.806–7.401) | 0.114 | 1.740 (0.452–6.697) | 0.421 |
| Others | 64 (18.29%) | 1.565 (0.473–5.180) | 0.463 | 1.581 (0.425–5.887) | 0.495 |
| A simple mastectomy | 63 (18.00%) | 1.000 | |||
| NA | 20 (5.71%) | ||||
| T stage | |||||
| T3/T4 | 56 (16.00%) | 2.980 (1.448–6.133) | 0.003 | 1.328 (0.469–3.760) | 0.594 |
| T1/T2 | 293 (83.71%) | 1.000 | 1.000 | ||
| NA | 1 (0.29%) | ||||
| N stage | |||||
| N2/N3 | 61 (17.43%) | 4.091 (1.996–8.384) | <0.001 | 3.525 (1.134–10.956) | 0.030 |
| N0/N1 | 286 (81.71%) | 1.000 | 1.000 | ||
| NA | 3 (0.86%) | ||||
| M stage | |||||
| M1 | 8 (2.29%) | 4.233 (1.716–10.440) | 0.002 | 1.741 (0.401–7.557) | 0.459 |
| M0 | 300 (85.71%) | 1.000 | 1.000 | ||
| NA | 42 (12.00%) | ||||
| ER status by IHC | |||||
| Positive | 271 (77.43%) | 2.996 (1.018–8.814) | 0.046 | 1.870 (0.372–9.417) | 0.448 |
| Negative | 64 (18.29%) | 1.000 | 1.000 | ||
| NA | 15 (4.29%) | ||||
| PR status by IHC | |||||
| Positive | 234 (66.89%) | 2.029 (0.863–4.772) | 0.105 | 0.925 (0.260–3.290) | 0.905 |
| Negative | 101 (28.86%) | 1.000 | 1.000 | ||
| NA | 15 (4.29%) | ||||
| HER2 status by IHC | |||||
| Positive | 72 (20.57%) | 0.791 (0.296–2.118) | 0.641 | 0.856 (0.217–3.378) | 0.826 |
| Overexpression | 51 (14.57%) | 1.043 (0.335–3.244) | 0.942 | 0.746 (0.151–3.682) | 0.724 |
| Negative | 174 (49.71%) | 1.000 | 1.000 | ||
| NA | 53 (15.14%) | ||||
| Chemotherapy | |||||
| Yes | 295 (84.29%) | 0.237 (0.100–0.565) | 0.001 | 0.214 (0.073–0.623) | 0.005 |
| No | 55 (15.71%) | 1.000 | 1.000 | ||
| DDX60 expression | |||||
| High | 175 (50%) | 0.7003 (0.353–1.391) | 0.309 | 0.816 (0.379–1.757) | 0.604 |
| Low | 175 (50%) | 1.000 | 1.000 | ||
Note. NA: data are not available; HR: hazard ratio; CI: confidence interval; IDC: invasive ductal carcinoma; MBC: special carcinomas, medullary carcinomas, mucinous carcinomas, mixed carcinomas, and others; ILC: invasive lobular carcinoma; IHC: immunohistochemistry.